Skip to Content
Søg Menu

Forbedret standardbehandling ved myelomatose

I denne MEDtalk har Agoston Gyula Szabo udvalgt og perspektiverer en række studier, fra dette års ASH-kongres, der belyser, om standardbehandlingen af myelomatose kan forbedres.
Agoston Gyula Szabo

Få adgang

Hvis du er læge, sygeplejerske eller anden sundhedsprofessionel kan du få adgang til hele artiklen ved at oprette en profil på BestPractice Nordic.

Relateret indhold

Hanne Norseth

Vaccinating Against Mutated RAS in Multiple Myeloma

/ Hanne Norseth
EHA24Myelomatose Play the Video 3:27
Frida Bugge Askeland

Treating MRD Relapse After First-Line Treatment May Prolong PFS and OS in Myeloma Patients

/ Frida Bugge Askeland
EHA24Myelomatose Play the Video 1:59
Elin Forsgren

Ibrutinib, Lenalidomide, and Rituximab in Relapsed Mantle Cell Lymphoma

/ Elin Forsgren
EHA24Myelomatose Play the Video 2:22
Bruno Paiva

Presidential Symposium: Innovative Tools for Disease Monitoring in Multiple Myeloma

/ Bruno Paiva
EHA24Myelomatose Play the Video 2:51
Sigrun Thorsteinsdottir

The Missing Link of Light Chain Smoldering Multiple Myeloma

/ Sigrun Thorsteinsdottir
EHA24Myelomatose Play the Video 4:00
Agoston Gyula Szabo

Dansk, investigator-initieret studie af lavdosis VEN-DEX hos patienter med RRMM og t(11;14) opnår en ORR på 50%

/ Agoston Gyula Szabo
EHA24Myelomatose Play the Video 01:31
Sigrun Thorsteinsdottir

New Insights into MM Heterogeneity Among Different Age Groups

/ Sigrun Thorsteinsdottir
EHA24Myelomatose Play the Video 02:51
Meletios Dimopoulos

Multiple Myeloma: Belantamab Mafodotin plus Pomalidomide and Dexamethasone Show Significant Higher PFS, Deep Response and OS vs Those of Standard of Care

/ Meletios A. Dimopoulos
EHA24Myelomatose Play the Video 04:07

EHA24: New Treatment Regimen Marks a Breakthrough for Patients with Multiple Myeloma

/ Isabella Rosa Staffe
EHA24Myelomatose
Back to top